Children who are on immunosuppressant drugs are more susceptible to infections than healthy children. Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. In such children, or in adults who have not had these diseases, particular care should be taken to avoid exposure. If exposed, therapy with variicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If chicken pox develops, treatment with antiviral agents may be considered.
Dutasteride was patented in 1996  and was first described in the scientific literature in 1997.  It was approved by the FDA for the treatment of BPH in November 2001 and was introduced into the United States market the following year under the brand name Avodart.  Dutasteride has subsequently been introduced in many other countries, including throughout Europe and South America .  The patent protection of dutasteride expired in November 2015 and the drug has since become available in the United States in a variety of low-cost generic formulations . 
Metabolic/Endocrine: Decreased glucose tolerance (see PRECAUTIONS ), increased serum levels of low-density lipoproteins and decreased levels of high-density lipoproteins (see PRECAUTIONS , Laboratory Tests ), increased creatine and creatinine excretion, increased serum levels of creatinine phosphokinase (CPK). Reversible changes in liver function tests also occur, including increased Bromsulphalein (BSP) retention and increases in serum bilirubin , glutamic-oxaloacetic transaminase ( SGOT ), and alkaline phosphatase .